CJ Bioscience Nominates Sangbae Yoon as New CEO
Plans Official Appointment After Shareholders' Meeting
Yoon Recognized for Leadership and Overseas Expansion at Huons
Current CEO Chun Jongshik to Remain as Advisor
On July 8, CJ Bioscience announced that it has nominated Sangbae Yoon, former CEO of Huons, as its new CEO.
CJ Bioscience plans to officially appoint Yoon as the new CEO following an extraordinary general meeting of shareholders and a board of directors meeting in the near future.
Yoon graduated from the College of Pharmacy and the graduate school at Chung-Ang University, and completed an MBA program at KAIST. He has held positions at Chong Kun Dang, Samsung C&T, GSK Korea, Dong-A ST, and Boryung Pharmaceutical, and served as CEO at Huons.
Notably, during his tenure as CEO of Huons, he led the company to double-digit sales growth. He was also recognized for enhancing the competitiveness of Korean pharmaceuticals in overseas markets, commercializing R&D achievements, strategically diversifying the business portfolio, and strengthening ESG management. In recognition of these achievements, he received the Presidential Commendation at the 2024 'Day of Medium-Sized Enterprises'.
Chun Jongshik, the current CEO of CJ Bioscience, will serve as an advisor going forward. Since the launch of CJ Bioscience, Chun has established the company's future growth foundation by advancing the lead pipeline 'CJRB-101' into multinational phase 1/2 clinical trials, acquiring assets from the UK-based microbiome company 4D Pharma to secure pipelines, and enhancing the AI drug discovery platform.
A CJ Bioscience representative stated, "We expect that the synergy between CEO nominee Yoon and current CEO Chun will strengthen our future competitiveness in the microbiome sector and lead to meaningful achievements such as technology exports."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
